These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 10384857)

  • 1. Pharmacokinetics of alendronate.
    Porras AG; Holland SD; Gertz BJ
    Clin Pharmacokinet; 1999 May; 36(5):315-28. PubMed ID: 10384857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate: an update of its use in osteoporosis.
    Sharpe M; Noble S; Spencer CM
    Drugs; 2001; 61(7):999-1039. PubMed ID: 11434454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of alendronate: an overview.
    Lin JH; Russell G; Gertz B
    Int J Clin Pract Suppl; 1999 Apr; 101():18-26. PubMed ID: 12669737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug clinics. The drug of the month. Alendronate (Fosamax)].
    Scheen AJ
    Rev Med Liege; 1998 Apr; 53(4):220-2. PubMed ID: 9641020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of alendronate sodium.
    Gertz BJ; Holland SD; Kline WF; Matuszewski BK; Porras AG
    Osteoporos Int; 1993; 3 Suppl 3():S13-6. PubMed ID: 8298197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate: a bisphosphonate for treatment of osteoporosis.
    Kirk JK; Spangler JG
    Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous alendronate.
    Cocquyt V; Kline WF; Gertz BJ; Van Belle SJ; Holland SD; DeSmet M; Quan H; Vyas KP; Zhang KE; De Grève J; Porras AG
    J Clin Pharmacol; 1999 Apr; 39(4):385-93. PubMed ID: 10197297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the oral bioavailability of alendronate.
    Gertz BJ; Holland SD; Kline WF; Matuszewski BK; Freeman A; Quan H; Lasseter KC; Mucklow JC; Porras AG
    Clin Pharmacol Ther; 1995 Sep; 58(3):288-98. PubMed ID: 7554702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis.
    Jeal W; Barradell LB; McTavish D
    Drugs; 1997 Mar; 53(3):415-34. PubMed ID: 9074843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
    Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
    Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
    Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
    Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
    Khan SA; Kanis JA; Vasikaran S; Kline WF; Matuszewski BK; McCloskey EV; Beneton MN; Gertz BJ; Sciberras DG; Holland SD; Orgee J; Coombes GM; Rogers SR; Porras AG
    J Bone Miner Res; 1997 Oct; 12(10):1700-7. PubMed ID: 9333131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease.
    Cremers SC; van Hogezand R; Bänffer D; den Hartigh J; Vermeij P; Papapoulos SE; Hamdy NA
    Osteoporos Int; 2005 Dec; 16(12):1727-30. PubMed ID: 15959617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
    Peris P; Torra M; Olivares V; Reyes R; Monegal A; Martínez-Ferrer A; Guañabens N
    Bone; 2011 Oct; 49(4):706-9. PubMed ID: 21742070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.